Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

 Breaking News
  • No posts were found

Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

Non-Small Cell Lung Cancer Pipeline 2024 | FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight

DelveInsight’s, Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Non-Small Cell Lung Cancer Research. Learn more about our innovative pipeline today! @ Non-Small Cell Lung Cancer Pipeline Outlook

Key Takeaways from the Non-Small Cell Lung Cancer Pipeline Report

  • June 2024:-Neal Ready MD PhD- This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery (adjuvant therapy) for stage IB, II or IIIA non-small cell lung cancer. Pembrolizumab is a type of immunotherapy that may enhance the ability of the immune system to fight off cancer. The study will investigate the effects of pembrolizumab on the immune system and how certain immune cells, called TILs (tumor infiltrating lymphocytes), respond to pembrolizumab. Previous studies suggest that pembrolizumab could alter the immune cells in a way that the the immune cells identify cancer cells.
  • June 2024:- Merck Sharp & Dohme LLC-A Phase 3, Multicenter, Randomized, Double-Blind Study of MK-7684 With Pembrolizumab as a Coformulation (MK-7684A) Versus Pembrolizumab Monotherapy as First Line Treatment for Participants With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer. The primary hypotheses are that coformulated pembrolizumab/vibostolimab is superior to pembrolizumab alone with respect to (1) overall survival (OS) in participants with programmed cell death 1 ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%, TPS ≥1% and TPS 1% to 49%; and (2) progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by blinded independent central review (BICR), in participants with PD-L1 TPS ≥1% and TPS ≥50%.
  • DelveInsight’s Non-Small Cell Lung Cancer pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Non-Small Cell Lung Cancer treatment.
  • The leading Non-Small Cell Lung Cancer Companies such as Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience – Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech, and others.
  • Promising Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.

Stay informed about the cutting-edge advancements in Non-Small Cell Lung Cancer Treatments. Download for updates and be a part of the revolution in oncology care @ Non-Small Cell Lung Cancer Clinical Trials Assessment

Non-Small-Cell Lung cancer (NSCLC) Drugs

  • V940: Merck Sharp & Dohme LLC

V940 is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient’s tumor. It is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed and produced based on the unique mutational signature of the DNA sequence of the patient’s tumor. Upon administration into the body, the algorithmically derived and RNA-encoded neoantigen sequences are endogenously translated and undergo natural cellular antigen processing and presentation, a key step in adaptive immunity. The drug is in Phase III stage for the treatment of NSCLC.

  • QL1706: Qilu Pharmaceutical Co., Ltd.

QL1706 is an investigational bifunctional antibody with additional anti-cytotoxic T lymphocyte antigen 4 (CTLA-4) antibody could increase the anti-tumor effect of anti-programmed cell death 1 (PD-1) antibody. QL1706 is a novel dual immune checkpoint blockade containing a mixture of anti-PD-1 IgG4 and anti-CTLA4 IgG1 antibodies produced by a single cell line. The drug is in Phase III stage for the treatment of NSCLC.

  • Zenocutuzumab (MCLA-128): Merus N.V.

Zenocutuzumab (MCLA-128; Zeno) is a Biclonics antibody that overcomes HER3 mediated NRG1 (or NRG1 fusion) signaling in tumor cells. Zeno docks on HER2, then binds to and blocks the NRG1 fusion-HER3 interaction and HER3 heterodimerization with HER2. It has a dual mechanism against cancer, as it prevents NRG1 fusions from binding to the protein HER3 and it blocks the interaction of HER3 with HER2, which the cancer cells depend on to survive and multiply. Currently, the drug is in Phase II stage for the treatment of NSCLC.

  • ZW49: Zymeworks BC Inc.

ZW49 (zanidatamab zovodotin) is a bispecific anti-HER2 ADC that is based on the same antibody framework as ZW25 but armed with a cytotoxic payload. A biparatopic (targeting two different non-overlapping epitopes on ERBB2, on extracellular domains 2 (ECD2) and 4 (ECD4). ZW25 is an anti-HER2 biparatopic antibody which binds to the same domains as trastuzumab and pertuzumab. ZW25 simultaneously binds two distinct sites on HER2, a protein expressed on many types of cancer cells. This unique design results in multiple mechanisms of action, including dual HER2 signal blockade, increased antibody binding, receptor clustering, and removal of HER2 from the cell surface, and potent effector function. ZW49 is in Phase I of clinical trials for the treatment of non-small cell lung cancer.

Learn more about Non-Small Cell Lung Cancer Drugs opportunities in our groundbreaking Non-Small Cell Lung Cancer Research and development projects @ Non-Small Cell Lung Cancer Unmet Needs

Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Non-Small Cell Lung Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Non-Small Cell Lung Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspectives

Scope of the Non-Small Cell Lung Cancer Pipeline Report

  • Coverage- Global
  • Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Non-Small Cell Lung Cancer Companies- Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience – Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech, and others.
  • Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, DS-1062a, Docetaxel, Pembrolizumab (MK-3475) 200 mg, Domvanalimab, Zimberelimab, Quemliclustat, BNT116, Cemiplimab, SKB264, Carboplatin, Osimertinib, and others.

For a detailed overview of our latest research findings and future plans, read the full details of Non-Small Cell Lung Cancer Pipeline on our website @ Non-Small Cell Lung Cancer Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Non-Small-Cell Lung cancer (NSCLC) : Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Non-Small-Cell Lung cancer (NSCLC) – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. V940: Merck Sharp & Dohme LLC
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Zenocutuzumab (MCLA-128): Merus N.V.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ZW49: Zymeworks BC Inc.
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Non-Small-Cell Lung cancer (NSCLC) Key Companies
  21. Non-Small-Cell Lung cancer (NSCLC) Key Products
  22. Non-Small-Cell Lung cancer (NSCLC) – Unmet Needs
  23. Non-Small-Cell Lung cancer (NSCLC) – Market Drivers and Barriers
  24. Non-Small-Cell Lung cancer (NSCLC) – Future Perspectives and Conclusion
  25. Non-Small-Cell Lung cancer (NSCLC) Analyst Views
  26. Non-Small-Cell Lung cancer (NSCLC) Key Companies
  27. Appendix 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories